Trial Profile
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2012
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Mesothelioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 25 Nov 2008 New trial record.